Evidence map›Paper›PMID 42842666›Full record

ArticleScience advances2026

Human trilayer engineered blood vessel reveals influence of fibroblasts on disease progression in model of Hutchinson-Gilford progeria.

Kevin L Shores, Xin D Gao, David R Liu, George A Truskey

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kevin L ShoresDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-6205-8318
Xin D GaoMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0003-2917-2060
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.ORCID 0000-0002-9943-7557
George A TruskeyDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-6885-4489

Funding

In Vitro Human Tissue-Engineered Blood Vessel Disease Model of ProgeriaR01HL138252 · NHLBI · DUKE UNIVERSITY · PI TRUSKEY, GEORGE A · 2017 to 2025
$4.7M
Leica Stellaris Confocal for a Campus-wide Shared ResourceS10OD034340 · OD · DUKE UNIVERSITY · PI CAMERON, LISA A. · 2024 to 2024
$686k
Investigating the Effects of Hutchinson-Gilford Progeria Syndrome Mutation Correction in Tissue-Engineered Blood VesselsF31HL172589 · NHLBI · DUKE UNIVERSITY · PI SHORES, KEVIN · 2024 to 2025
$85k
NHLBI NIH HHS F31 HL172589NHLBI NIH HHS R01 HL138252NIH HHS S10 OD034340
6 · The paper itself

Abstract

In vitro models of vascular disease have focused primarily on the pathophysiology of smooth muscle cell (SMC) or endothelial cell (EC). Adventitial fibroblasts can contribute to disease progression, but their specific influence is not well understood in different disease contexts. To elucidate fibroblast's impact on vascular pathology, we developed trilayer tissue-engineered blood vessels (TEBVs) with SMCs, ECs, and fibroblasts. We modeled atherosclerosis in the accelerated aging disease, Hutchinson-Gilford progeria syndrome (HGPS). HGPS fibroblasts substantially elevated several features of the vascular pathology. Correcting the HGPS-associated mutation using base editing returned many disease characteristics to healthy levels. By generating TEBVs with different combinations of vascular cells with or without the HGPS mutation, we found that fibroblasts contributed to extracellular matrix dysregulation and fibrotic signaling, SMCs to collagen accumulation, and ECs to inflammation. These results clarify the poorly understood influence of fibroblasts in progression of HGPS vascular pathology. The trilayer TEBV model could enable further mechanistic insights or therapeutic discovery for other vascular diseases.

Indexed as

Blood VesselsFibroblastsProgeriaTissue EngineeringAnimalsAtherosclerosisDisease ProgressionEndothelial CellsExtracellular MatrixHumansMyocytes, Smooth Muscle

Identifiers

PMID42842666
PMCPMC13644757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.